HEMOglobin Transfusion Threshold in Traumatic Brain Injury OptimizatioN: The HEMOTION Trial (HEMOTION)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03260478 |
Recruitment Status :
Recruiting
First Posted : August 24, 2017
Last Update Posted : August 17, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Traumatic Brain Injury Transfusion | Procedure: Red Blood Cells Transfusion | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 742 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Masking Description: | Open-label with blinded outcome evaluation. |
Primary Purpose: | Treatment |
Official Title: | HEMOglobin Transfusion Threshold in Traumatic Brain Injury OptimizatioN: The HEMOTION Trial |
Actual Study Start Date : | September 1, 2017 |
Estimated Primary Completion Date : | March 1, 2023 |
Estimated Study Completion Date : | November 1, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Liberal Transfusion Strategy
Patients will receive red blood cells transfusion if Hb ≤ 100 g/L.
|
Procedure: Red Blood Cells Transfusion
Transfusion of packed red blood cells unit(s). |
Experimental: Restrictive Transfusion Strategy
Patients will receive red blood cells transfusion if Hb ≤ 70 g/L.
|
Procedure: Red Blood Cells Transfusion
Transfusion of packed red blood cells unit(s). |
- extended Glasgow Outcome Scale (GOSe) [ Time Frame: 6 months ]Assessment of neurological outcome by the extended Glasgow Outcome Scale (GOSe)
- Mortality [ Time Frame: ICU, Hospital and at 6 months ]Assessment of patient mortality.
- Functional Independence Measure (FIM) [ Time Frame: 6 months ]Assessment of patient function.
- Quality of life (EQ-5D) [ Time Frame: 6 months ]Evaluation of the overall quality of life.
- Quality of life (Qolibri questionnaires) [ Time Frame: 6 months ]Evaluation of the quality of life specific to the TBI.
- Depression (PHQ-9) [ Time Frame: 6 months ]Assessment of depression.
- Complications related to transfusion [ Time Frame: 6 months ]Assessment of complications related to RBC transfusions.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Acute moderate to severe blunt TBI
- Glasgow Coma Score [GCS] ≤ 12
- Hb level ≤ 100 g/L
Exclusion Criteria:
- Patient has received transfusion after ICU admission
- Contraindications or known objection to transfusions
- Glasgow Coma Scale (GCS) of 3 with dilated fixed pupils.
- Patient is brain dead
- Active life-threatening bleeding with hemorrhagic shock or requiring urgent surgical procedure
- A decision to withold or withdraw life-sustaining therapies was made
- No fixed address

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03260478
Contact: Lucy Clayton, MSc | 1 (514) 345-4931 ext 6816 | hemotion@crchudequebec.ulaval.ca | |
Contact: Alexis Turgeon, MD MSc FRCPC | 1 (418) 649-0252 | alexis.turgeon@fmed.ulaval.ca |

Principal Investigator: | Alexis Turgeon, MD MSc FRCPC | CHU de Quebec-Université Laval Research Center | |
Principal Investigator: | François Lauzier, MD MSc FRCPC | CHU de Quebec-Université Laval Research Center | |
Principal Investigator: | Dean Fergusson, PhD | Ottawa Hospital Research Institute |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Dr Alexis Turgeon, Professor, CHU de Quebec-Universite Laval |
ClinicalTrials.gov Identifier: | NCT03260478 |
Other Study ID Numbers: |
MP-20-2018-3706 |
First Posted: | August 24, 2017 Key Record Dates |
Last Update Posted: | August 17, 2022 |
Last Verified: | August 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Traumatic Brain Injury (TBI) Red Blood Cells (RBC) Transfusion Intensive Care Unit (ICU) Transfusion Threshold |
Anemia Oxygen Delivery Neurocritical Care Critical Care Neurology and Trauma |
Brain Injuries Brain Injuries, Traumatic Wounds and Injuries Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Craniocerebral Trauma Trauma, Nervous System |